|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2000-8-14
|
|
pubmed:abstractText |
To assess in a pilot study the safety, tolerability, and technical feasibility of administering intravesical valrubicin immediately after transurethral resection of bladder tumors (TURBT) in patients with superficial bladder cancer and to evaluate the optimal dose of valrubicin and its systemic absorption.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1527-9995
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
232-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10925084-Administration, Intravesical,
pubmed-meshheading:10925084-Aged,
pubmed-meshheading:10925084-Carcinoma in Situ,
pubmed-meshheading:10925084-Combined Modality Therapy,
pubmed-meshheading:10925084-Doxorubicin,
pubmed-meshheading:10925084-Drug Administration Schedule,
pubmed-meshheading:10925084-Humans,
pubmed-meshheading:10925084-Male,
pubmed-meshheading:10925084-Pilot Projects,
pubmed-meshheading:10925084-Postoperative Complications,
pubmed-meshheading:10925084-Salvage Therapy,
pubmed-meshheading:10925084-Treatment Outcome,
pubmed-meshheading:10925084-Urinary Bladder,
pubmed-meshheading:10925084-Urinary Bladder Neoplasms,
pubmed-meshheading:10925084-Urination Disorders
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer.
|
|
pubmed:affiliation |
Veterans Affairs Medical Center, Memphis, Tennessee, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
